Panglima TNI Jenderal Agus Subiyanto Pamer Kasih Sayang ke Anaknya di SMA Taruna. SURYA.co.id - Momen Panglima TNI Jenderal Agus Subiyanto saat mengunjungi SMA Taruna Nusantara, Magelang, viral di ...

Novartis is on the final straight to approval of its spinal muscular atrophy (SMA) gene therapy Zolgensma in the EU, after getting a recommendation for approval from the CHMP. The positive opinion ...

Unresolved compliance issues at a manufacturing plant operated by Novo Nordisk have led to a complete response letter for Scholar Rock's lead drug for spinal muscular atrophy (SMA). The CRL is related ...

Novartis has received approval from the U.S. Food and Drug Administration for Itvisma, a treatment for spinal muscular atrophy. Dr. John Day is professor of neurology and pediatrics, director of the ...

Novartis has received an FDA approval for Itvisma, a new version of the company’s gene therapy Zolgensma, to treat older patients with spinal muscular atrophy (SMA). The approval comes more than six ...

SmartStop Self Storage REIT, Inc. (“SmartStop”) (NYSE: SMA) is a self-managed REIT with a fully integrated operations team of more than 1,000 self-storage professionals focused on growing the ...

PAMER KARYA - Pimpinan SMA Islam Athirah Bukit Baruga dan tamu undangan berfoto bersama usai pembukaan Athirah Baruga Education Expo (ABEE) Vol 4 di Wisma Kalla, Jalan Ratulangi, Makassar, Sabtu ...

Athirah Baruga Education Expo 2025 mengangkat tema “Crafting Smart Youth: Build Your Brand, Sharpen Your Skills". Pameran diisi dengan berbagai kegiatan, seperti presentasi produk siswa, product ...

FDA approved Itvisma, a gene therapy for SMA patients aged 2 and older. Itvisma delivers a healthy SMN1 gene via spinal injection in a one-time treatment. This expands gene therapy access to older ...

Itvisma, a one-time gene therapy for SMA, is approved for patients aged two and older, replacing the SMN1 gene without age or weight adjustments. Priced at $2.59 million, Itvisma is more ...